Back to top
more

Adverum Biotechnologies (ADVM)

(Delayed Data from NSDQ)

$2.51 USD

2.51
79,360

+0.19 (8.19%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $2.51 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for Catalyst (CPRX) This Earnings Season?

by Zacks Equity Research

Catalyst (CPRX) is expected to report first-quarter 2018 results on May 9, after the market closesa and investor's focus will be on pipeline and regulatory updates during the earnings call.

    Zacks Equity Research

    Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?

    by Zacks Equity Research

    In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.

      Zacks Equity Research

      What's in the Cards for Arena (ARNA) This Earnings Season?

      by Zacks Equity Research

      Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.

        Zacks Equity Research

        Will ACADIA (ACAD) Disappoint Investors This Earnings Season?

        by Zacks Equity Research

        ACADIA (ACAD) is expected to release first-quarter 2018 results on May 8 and provide updates on its drug, Nuplazid.

          Zacks Equity Research

          Is a Beat in Store for Adverum (ADVM) This Earnings Season?

          by Zacks Equity Research

          Adverum Biotechnologies (ADVM) is expected to report first-quarter 2018 results, on May 8 and provide updates on its pipeline candidates.

            Zacks Equity Research

            GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?

            by Zacks Equity Research

            GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.

              Zacks Equity Research

              What's in Store for Intercept (ICPT) This Earnings Season?

              by Zacks Equity Research

              Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).

                Zacks Equity Research

                Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?

                by Zacks Equity Research

                Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.

                  Zacks Equity Research

                  Will Segmental Revenues Aid Cooper's (COO) Q1 Earnings?

                  by Zacks Equity Research

                  CooperSurgical sales and broad product spectrum are key catalysts for Cooper's (COO) Q1 earnings. However, falling estimates of other segments are likely to mar prospects.

                    Zacks Equity Research

                    Is a Beat in Store for Adverum (ADVM) This Earnings Season?

                    by Zacks Equity Research

                    Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.

                      Zacks Equity Research

                      Adverum Biotechnologies (ADVM) Jumps: Stock Rises 7.9%

                      by Zacks Equity Research

                      Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.

                        Zacks Equity Research

                        What's in the Cards for Adverum (ADVM) This Earnings Season?

                        by Zacks Equity Research

                        Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                          Zacks Equity Research

                          Adverum Biotechnologies (ADVM) in Focus: Stock Moves 9.7% Higher

                          by Zacks Equity Research

                          Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

                            Zacks Equity Research

                            Marinus Stock Surges on Successful Phase II Epilepsy Study

                            by Zacks Equity Research

                            Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.

                              Zacks Equity Research

                              Is Adverum Biotechnologies an Incredible Momentum Stock? 3 Reasons Why ADVM Will Be Tough to Beat

                              by Zacks Equity Research

                              Adverum Biotechnologies (ADVM) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.

                                Zacks Equity Research

                                What's in the Cards for Adverum (ADVM) this Earnings Season?

                                by Zacks Equity Research

                                Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.

                                  Zacks Equity Research

                                  What's in Store for Adverum (ADVM) in Q1 Earnings?

                                  by Zacks Equity Research

                                  Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.

                                    Zacks Equity Research

                                    Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?

                                    by Zacks Equity Research

                                    Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.